Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 25 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 21 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History